| Literature DB >> 35273329 |
Sung Kyun Kim1,2, Seok Jin Hong1, Dae Myoung Yoo3, Chanyang Min3,4, Hyo Geun Choi5,6.
Abstract
We hypothesized that asthma/chronic obstructive pulmonary disease (COPD) might increase the risk of chronic otitis media (COM), as asthma or COPD affects other diseases. The aim of this research was to investigate whether the incidence of COM is affected by a diagnosis of asthma or COPD in patients compared to matched controls from the national health screening cohort. A COM group (n = 11,587) and a control group that was 1:4 matched for age, sex, income, and residence area (n = 46,348) were selected. The control group included participants who never received treatment for COM from Korean National Health Insurance Service-Health Screening Cohort from 2002 to 2015. The crude and adjusted odds ratios (ORs) of previous asthma/COPD before the index date for COM were analyzed using conditional logistic regression. The analyses were stratified by age, sex, income, and region of residence. The period prevalence of asthma (17.5% vs. 14.3%, p < 0.001) and COPD (6.6% vs. 5.0%, p < 0.001) were significantly higher in the COM group than in the control group. In addition, the odds of asthma and COPD were significantly higher in the COM group than in the control group. Both asthma (adjusted OR 1.23, 95% confidence interval [CI] 1.16-1.31, p < 0.001) and COPD (adjusted OR 1.23, 95% CI 1.13-1.35, p < 0.001) increased the ORs for COM. This positive association between asthma/COPD and COM indicates that asthma/COPD might increase the incidence of COM.Entities:
Mesh:
Year: 2022 PMID: 35273329 PMCID: PMC8913729 DOI: 10.1038/s41598-022-08287-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
General characteristics of participants.
| Characteristics | Total participants | ||
|---|---|---|---|
| COM | Control | p-value | |
| 1.000 | |||
| 40–44 | 315 (2.7) | 1260 (2.7) | |
| 45–49 | 1318 (11.4) | 5272 (11.4) | |
| 50–54 | 1962 (16.9) | 7848 (16.9) | |
| 55–59 | 2088 (18.0) | 8352 (18.0) | |
| 60–64 | 1887 (16.3) | 7548 (16.3) | |
| 65–69 | 1729 (14.9) | 6916 (14.9) | |
| 70–74 | 1273 (11.0) | 5092 (11.0) | |
| 75–79 | 669 (5.8) | 2676 (5.8) | |
| 80–84 | 282 (2.4) | 1128 (2.4) | |
| 85 + | 64 (0.6) | 256 (0.6) | |
| 1.000 | |||
| Males | 5430 (46.9) | 21,720 (46.9) | |
| Females | 6157 (53.1) | 24,628 (53.1) | |
| 1.000 | |||
| 1 (lowest) | 1889 (16.3) | 7556 (16.3) | |
| 2 | 1566 (13.5) | 6264 (13.5) | |
| 3 | 1896 (16.4) | 7584 (16.4) | |
| 4 | 2530 (21.8) | 10,120 (21.8) | |
| 5 (highest) | 3706 (32.0) | 14,824 (32.0) | |
| 1.000 | |||
| Urban | 4824 (41.6) | 19,296 (41.6) | |
| Rural | 6763 (58.4) | 27,052 (58.4) | |
| Total cholesterol (mg/dL, mean, SD) | 199.0 (38.1) | 199.7 (38.2) | 0.080 |
| SBP (mmHg, mean, SD) | 126.5 (16.9) | 127.1 (17.2) | 0.001† |
| DBP (mmHg, mean, SD) | 78.2 (10.7) | 78.6 (10.9) | 0.001† |
| Fasting blood glucose (mg/dL, mean, SD) | 99.6 (29.9) | 100.2 (29.4) | 0.103 |
| 0.083 | |||
| Underweight | 255 (2.2) | 1180 (2.6) | |
| Normal | 4049 (34.9) | 16,340 (35.3) | |
| Overweight | 3244 (28.0) | 12,617 (27.2) | |
| Obese I | 3700 (31.9) | 14,752 (31.8) | |
| Obese II | 339 (2.9) | 1459 (3.2) | |
| 0.002* | |||
| Nonsmoker | 8641 (74.6) | 34,055 (73.5) | |
| Past smoker | 1204 (10.4) | 4707 (10.2) | |
| Current smoker | 1742 (15.0) | 7586 (16.4) | |
| 0.001* | |||
| < 1 time a week | 8422 (72.7) | 32,953 (71.1) | |
| ≥ 1 time a week | 3165 (27.3) | 13,395 (28.9) | |
| < 0.001* | |||
| 0 | 7897 (68.2) | 32,698 (70.6) | |
| 1 | 1726 (14.9) | 5989 (12.9) | |
| 2 | 901 (7.8) | 3629 (7.8) | |
| 3 | 488 (4.2) | 1742 (3.8) | |
| ≥ 4 | 575 (5.0) | 2290 (4.9) | |
| COPD (n, %) | 763 (6.6) | 2317 (5.0) | < 0.001* |
| Asthma (n, %) | 2028 (17.5) | 6610 (14.3) | < 0.001* |
CCI Charlson comorbidity index, COM chronic otitis media, COPD chronic obstructive pulmonary disease, DBP diastolic blood pressure, SBP systolic blood pressure, SD standard deviation.
*Chi-square test. Significance at p < 0.05.
†Wilcoxon rank-sum test. Significance at p < 0.05.
‡Obesity (BMI, body mass index, kg/m2) was categorized as < 18.5 (underweight), ≥ 18.5 to < 23 (normal), ≥ 23 to < 25 (overweight), ≥ 25 to < 30 (obese I), and ≥ 30 (obese II).
§CCI scores were calculated without pulmonary disease.
Odds ratios (95% confidence interval) of asthma for chronic otitis media with subgroup analyses according to age, sex, income, and region of residence.
| Characteristics | No. of COM/No. of participants (%) | Odds ratios for COM | |||
|---|---|---|---|---|---|
| Crude† | p-value | Adjusted†,‡ | p-value | ||
| Asthma | 2028/8638 (23.5) | 1.29 (1.22–1.36) | < 0.001* | 1.23 (1.16–1.31) | < 0.001* |
| Control | 9559/49,297 (19.4) | 1 | 1 | ||
| Asthma | 717/2899 (24.7) | 1.37 (1.25–1.50) | < 0.001* | 1.34 (1.22–1.47) | < 0.001* |
| Control | 4966/25,516 (19.5) | 1 | 1 | ||
| Asthma | 1311/5739 (22.8) | 1.24 (1.16–1.33) | < 0.001* | 1.18 (1.09–1.27) | < 0.001* |
| Control | 4593/23,781 (19.3) | 1 | 1 | ||
| Asthma | 771/3302 (23.4) | 1.27 (1.16–1.38) | < 0.001* | 1.20 (1.09–1.32) | < 0.001* |
| Control | 4659/23,848 (19.5) | 1 | 1 | ||
| Asthma | 1257/5336 (23.6) | 1.30 (1.21–1.40) | < 0.001* | 1.26 (1.17–1.36) | < 0.001* |
| Control | 4900/25,449 (19.3) | 1 | 1 | ||
| Asthma | 978/4111 (23.8) | 1.32 (1.22–1.43) | < 0.001* | 1.27 (1.17–1.38) | < 0.001* |
| Control | 4373/22,644 (19.3) | 1 | 1 | ||
| Asthma | 1050/4527 (23.2) | 1.26 (1.17–1.36) | < 0.001* | 1.20 (1.11–1.30) | < 0.001* |
| Control | 5186/26,653 (19.5) | 1 | 1 | ||
| Asthma | 825/3369 (24.5) | 1.37 (1.26–1.50) | < 0.001* | 1.33 (1.21–1.45) | < 0.001* |
| Control | 3999/20,751 (19.3) | 1 | 1 | ||
| Asthma | 1203/5269 (22.8) | 1.23 (1.15–1.32) | < 0.001* | 1.17 (1.09–1.27) | < 0.001* |
| Control | 5560/28,546 (19.5) | 1 | 1 | ||
CCI Charlson comorbidity index, COM chronic otitis media, COPD chronic obstructive pulmonary disease, DBP diastolic blood pressure, SBP systolic blood pressure.
*Conditional logistic regression, Significance at p < 0.05.
†Models were stratified by age, sex, income, and region of residence.
‡Adjusted for obesity, smoking, alcohol consumption, CCI scores, total cholesterol, SBP, DBP, fasting blood glucose, and COPD.
Odds ratios (95% confidence interval) of COPD for COM with subgroup analyses according to age, sex, income, and region of residence.
| Characteristics | No. of COM/No. of participants (%) | Odds ratios for COM | |||
|---|---|---|---|---|---|
| Crude† | p-value | Adjusted†,‡ | p-value | ||
| COPD | 763/3080 (24.8) | 1.36 (1.25–1.48) | < 0.001* | 1.23 (1.13–1.35) | < 0.001* |
| Control | 10,824/54,855 (19.7) | 1 | 1 | ||
| COPD | 151/591 (25.5) | 1.38 (1.15–1.67) | 0.001* | 1.24 (1.02–1.50) | 0.031* |
| Control | 5532/27,824 (19.9) | 1 | 1 | ||
| COPD | 612/2489 (24.6) | 1.35 (1.23–1.49) | < 0.001* | 1.25 (1.13–1.39) | < 0.001* |
| Control | 5292/27,031 (19.6) | 1 | 1 | ||
| COPD | 394/1632 (24.1) | 1.32 (1.17–1.49) | < 0.001* | 1.20 (1.06–1.37) | 0.005* |
| Control | 5036/25,518 (19.7) | 1 | 1 | ||
| COPD | 369/1448 (25.5) | 1.40 (1.24–1.59) | < 0.001* | 1.27 (1.12–1.44) | < 0.001* |
| Control | 5788/29,337 (19.7) | 1 | 1 | ||
| COPD | 372/1505 (24.7) | 1.36 (1.20–1.53) | < 0.001* | 1.21 (1.06–1.38) | 0.005* |
| Control | 4979/25,250 (19.7) | 1 | 1 | ||
| COPD | 391/1575 (24.8) | 1.36 (1.21–1.54) | < 0.001* | 1.25 (1.10–1.42) | 0.001* |
| Control | 5845/29,605 (19.7) | 1 | 1 | ||
| COPD | 258/1024 (25.2) | 1.38 (1.19–1.60) | < 0.001* | 1.23 (1.06–1.43) | 0.008* |
| Control | 4566/23,096 (19.8) | 1 | 1 | ||
| COPD | 505/2056 (24.6) | 1.35 (1.21–1.50) | < 0.001* | 1.24 (1.11–1.39) | < 0.001* |
| Control | 6258/31,759 (19.7) | 1 | 1 | ||
CCI Charlson comorbidity index, COM chronic otitis media, COPD chronic obstructive pulmonary disease, DBP diastolic blood pressure, SBP systolic blood pressure.
*Conditional logistic regression, Significance at p < 0.05.
†Models were stratified by age, sex, income, and region of residence.
‡Adjusted for obesity, smoking, alcohol consumption, CCI scores, total cholesterol, SBP, DBP, fasting blood glucose, and asthma.
Figure 1A schematic illustration of the participant selection process. Of a total of 514,866 participants, 11,587 of COM participants were matched with 46,348 of control participants for age, sex, income, and region of residence.